Cellular therapy in lymphoma-Reference-Cited by-同舟云学术

Cellular therapy in lymphoma

Published:2023-06-29 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Sureda Anna¹,Lugtenburg Pieternella J.²,Kersten Marie José³,Subklewe Marion⁴⁵,Spanjaart Anne³,Shah Nirali N⁶,Kerbauy Lucila N⁷,Roddie Clarie⁸,Pennings Elise R. A.³^ORCID,Mahuad Carolina⁹,Poon Michelle¹⁰,Hendricks Candice L¹¹¹²,Kamdar Manali¹³,Jacobson Caron¹⁴^ORCID

Affiliation:

1. Clinical Hematology Department Institut Catala d’Oncologia – Hospitalet Institut d’Investigatcions Biomediques de Bellvitge (IDIBELL) Universitat de Barcelona Barcelona Spain

2. Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands

3. Department of Hematology Amsterdam Universitair Medische Centra Amsterdam The Netherlands

4. Department of Medicine III University Hospital LMU Munich Germany

5. Laboratory for Translational Cancer Immunology LMU Gene Center Munich Germany

6. Pediatric Oncology Branch Center for Cancer Research (CCR) National Cancer Institute (NCI) NIH Bethesda Maryland USA

7. Departments of Stem Cell Transplantation and Hemotherapy/Cellular Therapy Hospital Israelita Albert Einstein Sao Paolo Brazil

8. Research Department of Haematology Cancer Institute University College London London UK

9. Hematology Service Department of Internal Medicine Deutsches Hospital Buenos Aires Argentina

10. Department of Haematology‐Oncology National University Cancer Institute Singapore Singapore

11. Institute for Cellular and Molecular Medicine Department of Immunology Faculty of Health Sciences University of Pretoria Pretoria South Africa

12. SAMRC Extramural Unit for Stem Cell Research and Therapy Faculty of Health Sciences University of Pretoria Pretoria South Africa

13. University of Colorado Aurora Colorado USA

14. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Abstract

AbstractCD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has had a dramatic impact on the natural history and survival of patients with high‐risk B‐cell non‐Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T‐cell therapy, written by an International community of lymphoma experts, who also happen to be women.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3200

Reference81 articles.

1. CAR T-Cell Therapy in Large B-Cell Lymphoma

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

4. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

5. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study;Molecular Cancer;2023-12-09

2. Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H₂Mab‐77‐mG_2a‐f;Cancer Science;2023-11-09

3. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?;Hematological Oncology;2023-11-08

4. Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma;Current Oncology Reports;2023-10-20